Josh Eizen

Mr. Eizen is AN2’s Chief Legal Officer and Secretary, responsible for managing the company’s legal affairs and compliance functions. He has been practicing law for over 20 years, with roles spanning industry, government, and private practice. Before joining AN2, Mr. Eizen held senior legal and compliance positions at Jazz Pharmaceuticals, GW Pharmaceuticals, Jansen Pharmaceuticals, and Actelion Pharmaceuticals. As the U.S. General Counsel at GW, he guided the company on corporate, commercialization, regulatory, government affairs, and employment matters. He supported the launch and commercialization of Epidiolex, GW’s $7.2b sale to Jazz Pharmaceuticals, its $350m follow-on offering (2018), and various pre-commercial and regulatory strategies for GW’s neuroscience and orphan-disease pipeline. Earlier in his career, Mr. Eizen was Associate Chief Counsel for Enforcement at the Food and Drug Administration. As a government attorney for FDA, he handled investigations and prosecutions involving off-label promotion, manufacturing violations, product integrity, and public health outbreaks. Mr. Eizen began his legal career in private practice at a corporate tax and litigation firm.